Upcoming Webinar: Novel Platforms for Preclinical Antibody Discovery
Antibodies have become powerful preventive and therapeutic tools against infectious diseases, cancers, autoimmune disorders, and many other conditions. However, conventional antibody discovery approaches continue to face major limitations, including inefficiency, high costs, high failure rates, logistical barriers, limited scalability, and long development timelines.
We are pleased to invite Dr. Ivelin Georgiev to present his latest work on developing and validating novel wet-lab and AI-based platforms for preclinical antibody discovery.
In this webinar, Dr. Georgiev will discuss how these innovative platforms are designed to improve the efficiency, scalability, and success rate of monoclonal antibody discovery. He will also highlight how integrated experimental and computational approaches can help identify antibody candidates with challenging phenotypes that are difficult—or even impossible—to achieve using traditional discovery methods.
Key points to be discussed during the session:
- How novel wet-lab and AI-based platforms can address key bottlenecks in traditional antibody discovery
- The potential of these platforms to reduce discovery costs, timelines, and failure rates in preclinical antibody development
- How advanced discovery strategies can enable the identification of monoclonal antibody candidates with difficult-to-achieve functional phenotypes
Ivelin Georgiev, PhD
Professor, Vanderbilt University Medical Center
Dr. Georgiev received his Ph.D. in Computer Science from Duke University, after which he served as a staff scientist and co-head of Structural Bioinformatics at the Vaccine Research Center, NIH. Dr. Georgiev is currently a Professor in the Departments of Pathology, Microbiology, and Immunology; Biochemistry; Biomedical Informatics; Computer Science; and Chemical and Biomolecular Engineering at Vanderbilt. He is also the Director for the Vanderbilt Ph.D. Program in Chemical and Physical Biology, and is an Associate Director for the Vanderbilt Institute for Infection, Immunology, and Inflammation. Dr. Georgiev is the founding Director of the Vanderbilt Center for Computational Microbiology and Immunology, focused on supporting research, educational, and strategic efforts that aim to employ the power of computation toward the development and application of innovative approaches for treatment and prevention of disease and for enhancement of human health. Dr. Georgiev has published over 100 peer-reviewed manuscripts in top-tier journals, including Science, Nature, Cell, and many others; and is an inventor on numerous issued patents.